Full Press Release Details
AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients
Md., June 12, 2025 (GLOBE NEWSWIRE) - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the
"Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable
the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading
UK-based contract research organization (CRO) specializing in drug discovery. Through this collaboration, Sygnature will introduce BullFrog
Data Networks -BullFrog's proprietary AI-driven data insights platform powered by the bfLEAP engine-to
Sygnature's global client base of relevant biopharma companies.
collaboration marks a significant commercial milestone for BullFrog AI and is expected to greatly accelerate brand recognition and user
uptake to generate between $15-$30 million in revenue for BullFrog AI through 2028.
collaboration agreement with Sygnature Discovery is a major step forward in our mission to democratize access to cutting-edge AI tools
that accelerate drug discovery," said Vin Singh, Founder and CEO of BullFrog AI. "By highlighting BullFrog Data Networks
as part of Sygnature's comprehensive suite of discovery solutions, we build brand recognition within a high-quality global client
base that is actively engaged in early-stage target discovery-an area where our platform adds tremendous value."
Data Networks accelerates the exploration of complex, high-dimensional, multi-modal datasets, uncovering hidden relationships
and novel pathways critical to understanding disease biology. This powerful platform supports vital research applications including early
target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization. Delivered
through an intuitive, visual, and disease-centric interface, BullFrog Data Networks empowers researchers to confidently make informed,
strategic decisions faster than ever before.
Discovery is committed to offering a range of best-in-class tools to our clients across the drug discovery continuum," said Stuart
Onions, Chief Technical Officer at Sygnature Discovery. "BullFrog AI's platform further complements our capabilities in target
discovery and data interpretation, helping relevant clients who express an interest in the technology to unlock the full potential of
their datasets and improve R&D efficiency and success rates."
AI's scalable Data Networks offering was designed to meet the needs of small to mid-sized biopharma companies, a segment often
underserved by existing bioinformatics solutions. Through this collaboration, BullFrog and Sygnature Discovery can accelerate innovation
across a wide range of therapeutic areas.
AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading
research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP platform to analyze complex biological
data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
more information visit BullFrog AI at: https://bullfrogai.com
press release contains forward-looking statements, including the revenues to be generated in connection with this collaboration. We base
these forward-looking statements on our expectations and projections about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance
and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements
by those that are not historical in nature, particularly those that use terminology such as "may," "should,"
"could," "will," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or "hopes"
or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including:
our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our
partners' ability to market and sell our offerings and servicings, including BullFrog Data Networks and the competitive
environment of our business. In particular, there can be no assurance as to the actual revenues to be received from this collaboration,
which are subject to a number of factors and risks, such as Sygnature's ability to effectively sell BullFrog Data Networks
to its clients. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time
by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties,
and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties
and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our
representatives might not occur.